Is Biotricity, Inc. overvalued or undervalued?

As of 14 February 2020, the valuation grade for Biotricity, Inc. moved from does not qualify to risky, indicating increased caution for investors. The company appears to be overvalued, as evidenced by a Price to Book Value of -0.44 and an EV to EBITDA ratio of -8.26, both of which suggest significant financial distress. Additionally, the company's P/E ratio is not applicable due to it being loss-making, further complicating its valuation.
In comparison to its peers, Biotricity's valuation metrics are concerning; for instance, CareCloud, Inc. has a P/E of 12.655, while Biotricity's is -3.7032, highlighting a stark contrast in financial health. Other risky peers like Intellinetics, Inc. and Zenvia, Inc. also show negative valuations, with EV to EBITDA ratios of -49.2573 and 4.5867, respectively. Notably, Biotricity's recent stock performance has been volatile, with a YTD return of 114.87% compared to the S&P 500's 12.22%, yet this is overshadowed by a 3Y return of -90.97%, indicating long-term challenges.